Erwinia asparaginase in pediatric acute lymphoblastic leukemia

Expert Opinion on Biological Therapy

Volumn 12, Issue 10, 2012, Pages 1407-1414

  Salzer, Wanda ^a   Seibel, Nita ^a   Smith, Malcolm ^a  

^a NCI   (United States)

Author keywords

Acute lymphoblastic leukemia; Allergy; Antibody; Erwinia asparaginase; Treatment

Indexed keywords

ASPARAGINASE; ASPARAGINASE MACROGOL; IMMUNOGLOBULIN G ANTIBODY;

ACUTE LYMPHOBLASTIC LEUKEMIA; AMINOTRANSFERASE BLOOD LEVEL; BLEEDING; CHILDHOOD DISEASE; CHILDHOOD LEUKEMIA; CLINICAL EFFECTIVENESS; CLINICAL TRIAL (TOPIC); DOSAGE SCHEDULE COMPARISON; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG TOLERABILITY; HUMAN; HYPERBILIRUBINEMIA; LIVER FUNCTION TEST; PANCREATITIS; REVIEW; SIDE EFFECT; THROMBOSIS;

ANTINEOPLASTIC AGENTS; ASPARAGINASE; CHILD; ERWINIA; HUMANS; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

ERWINIA; ESCHERICHIA COLI;

EID: 84866242603     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2012.718327     Document Type: Review

References (80)

1. Dolowy WC, Henson D, Cornet J, Sellin H. Toxic and antineoplastic effects of L-asparaginase. Study of mice with lymphoma and normal monkeys and report on a child with leukemia. Cancer 1966;19(12):1813-19
2. Appel IM, Kazemier KM, Boos J, et al. Pharmacokinetic, pharmacodynamic and intracellular effects of PEG-asparaginase in newly diagnosed childhood acute lymphoblastic leukemia: Results from a single agent window study. Leukemia 2008;22(9):1665-79
3. Capizzi RL, Bertino JR, Skeel RT, et al. L-asparaginase: Clinical, biochemical, pharmacological, and immunological studies. Ann Intern Med 1971;74(6):893-901
4. Jaffe N, Traggis D, Das L, et al. L-asparaginase in the treatment of neoplastic diseases in children. Cancer Res 1971;31(7):942-9
5. Nesbit ME, Ertel I, Hammond GD. L-Asparaginase as a single agent in acute lymphocytic leukemia: Survey of studies form Childrens Cancer Study Group. Cancer Treat Rep 1981;65(Suppl 4):101-7
6. Sutow WW, Garcia F, Starling KA, et al. L-asparaginase therapy in children with advanced leukemia: The Southwest Cancer Chemotherapy Study Group. Cancer 1971;28(4):819-24
7. Tallal L, Tan C, Oettgen H, et al. E. coli L-asparaginase in the treatment of leukemia and solid tumors in 131 children. Cancer 1970;25(2):306-20
8. Pui CH, Robison LL, Look AT. Acute lymphoblastic leukaemia. Lancet 2008;371(9617):1030-43
9. Clavell LA, Gelber RD, Cohen HJ, et al. Four-agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia. N Engl J Med 1986;315(11):657-63
10. Nachman JB, Sather HN, Sensel MG, et al. Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. N Engl J Med 1998;338(23):1663-71
11. Amylon MD, Shuster J, Pullen J, et al. Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: A Pediatric Oncology Group study. Leukemia 1999;13(3):335-42
12. Schrappe M, Camitta B, Pui C-H. Long-term results of large prospective trials in childhood acute lymphoblastic leukemia. Nature Publishing Group; Leukemia: 2000. p. 2193
13. Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med 2006;354(2):166-78
14. Asselin B, Whitin J, Coppola D, et al. Comparative pharmacokinetic studies of three asparaginase preparations. J Clin Oncol 1993;11(9):1780-6
15. Albertsen BK, Schrder H, Ingerslev J, et al. Comparison of intramuscular therapy with Erwinia asparaginase and asparaginase Medac: Pharmacokinetics, pharmacodynamics, formation of antibodies and influence on the coagulation system. Br J Haematol 2001;115(4):983-90
16. Avramis VI, Panosyan EH. Pharmacokinetic/pharmacodynamic relationships of asparaginase formulations: The past, the present and recommendations for the future. Clin Pharmacokinet 2005;44(4):367-93
17. Avramis V, Spence S. Clinical pharmacology of asparaginases in the United States: Asparaginase population pharmacokinetic and pharmacodynamic (PK-PD) models (NONMEM) in adult and pediatric ALL patients. J Pediatr Hematol Oncol 2007;29(4):239-47
18. Panetta JC, Gajjar A, Hijiya N, et al. Comparison of Native E. coli and PEG Asparaginase Pharmacokinetics and Pharmacodynamics in Pediatric Acute Lymphoblastic Leukemia. Clin Pharmacol Ther 2009;86(6):651-8
19. Silverman LB, Gelber RD, Dalton VK, et al. Improved outcome for children with acute lymphoblastic leukemia: Results of Dana-Farber Consortium Protocol 91-01. Blood 2001;97(5):1211-18
20. Ho DHW, Whitecar JP Jr, Luce JK, Frei E III. L-asparagine requirement and the effect of L-asparaginase on the normal and leukemic human bone marrow. Cancer Res 1970;30(2):466-72
21. Broome JD. Studies on the mechanism of tumor inhibition by L-asparaginase. Effects of the enzyme on asparagine levels in the blood, normal tissues, and 6C3HED lymphomas of mice: differences in asparagine formation and utilization in asparaginase-sensitive and -resistant lymphoma cells. J Exper Med 1968;127(6):1055-72
22. Stams WAG, den Boer M, Holleman A, et al. Asparagine synthetase expression is linked with L-asparaginase resistance in TEL-AML1-negative but not TEL-AML1-positive pediatric acute lymphoblastic leukemia. Blood 2005;105(11):4223-5
23. Appel IM, den Boer ML, Meijerink JPP, et al. Up-regulation of asparagine synthetase expression is not linked to the clinical response L-asparaginase in pediatric acute lymphoblastic leukemia. Blood 2006;107(11):4244-9
24. Iwamoto S, Mihara K, Downing J, et al. Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase. J Clinl Invest 2007;117(4):1049-57
25. Aslanian AM, Fletcher BS, Kilberg MS. Asparagine synthetase expression alone is sufficient to induce l-asparaginase resistance in MOLT-4 human leukaemia cells. Biochem J 2001;357(1):321-8
26. Haskell CM, Canellos GP. L-asparaginase resistance in human leukemia-asparagine synthetase. Biochem Pharmacol 1969; 18(10):2578-80
27. Hutson RG, Kitoh T, Moraga Amador DA, et al. Amino acid control of asparagine synthetase: Relation to asparaginase resistance in human leukemia cells. American J Physiol 1997;272(5):C1691-C9
28. Avramis VI, Sencer S, Periclou AP, et al. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of hildren with newly diagnosed standard-risk acute lymphoblastic leukemia: A Children's Cancer Group study. Blood 2002;99(6):1986-94
29. Riccardi R, Holcenberg JS, Glaubiger DL, et al. L-asparaginase pharmacokinetics and asparagine levels in cerebrospinal fluid of rhesus monkeys and humans. Cancer Res 1981;41(11 Pt 1):4554-8
30. Boos J, Werber G, Ahlke E, et al. Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations. Eur J Cancer 1996;32(9):1544-50
31. Ahlke E, Nowak-Gottl U, Schulze-Westhoff P, et al. Dose reduction of asparaginase under pharmacokinetic and pharmacodynamic control during induction therapy in children with acute lymphoblastic leukaemia. Br J Haematol 1997;96(4):675-81
32. Klug Albertsen B, Schmiegelow K, Schroder H, et al. Anti-Erwinia asparaginase antibodies during treatment of childhood acute lymphoblastic leukemia and their relationship to outcome: A case-control study. Cancer Chemother Pharmacol 2002;50(2):117-20
33. Vieira Pinheiro JP, Ahlke E, Nowak-Gottl U, et al. Pharmacokinetic dose adjustment of Erwinia asparaginase in protocol II of the paediatric ALL/NHL-BFM treatment protocols. Br J Haematol 1999;104(2):313-20
34. Rizzari C, Zucchetti M, Conter V, et al. L-asparagine depletion and L-asparaginase activity in children with acute lymphoblastic leukemia receiving i.m. or i.v. Erwinia C. or E. coli L-asparaginase as first exposure. Ann Oncol 2000;11(2):189-93
35. Zalewska-Szewczyk B, Andrzejewski W, Młynarski W, et al. The anti-asparagines antibodies correlate with L-asparagines activity and may affect clinical outcome of childhood acute lymphoblastic leukemia. Leuk lymphoma 2007;48(5):931-6
36. Nesbit M, Chard R, Evans A, et al. Evaluation of intramuscular versus intravenous administration of L-asparaginase in childhood leukemia. Am J Pediatr Hematol Oncol 1979;1(1):9-13
37. Panosyan EH, Seibel NL, Martin-Aragon S, et al. Asparaginase antibody and asparaginase activity in children with higher-risk acute lymphoblastic leukemia: Children's Cancer Group Study CCG-1961. J Pediatr Hematol Oncol 2004;26(4):217-26
38. Albertsen BK, Schroder H, Jakobsen P, et al. Antibody formation during intravenous and intramuscular therapy with Erwinia asparaginase. Med Pediatr Oncol 2002;38(5):310-16
39. Muller HJ, Beier R, Lning L, et al. Pharmacokinetics of native Escherichia coli asparaginase (Asparaginase medac) and hypersensitivity reactions in ALL-BFM 95 reinduction treatment. Br J Haematol 2001;114(4):794-9
40. Seibel NL, Steinherz PG, Sather HN, et al. Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: A report from the Children's Oncology Group. Blood 2008;111(5):2548-55
41. Woo MH, Hak LJ, Storm MC, et al. Hypersensitivity or development of antibodies to asparaginase does not impact treatment outcome of childhood acute lymphoblastic leukemia. J Clin Oncol 2000;18(7):1525-32
42. Wacker P, Land V, Camitta B, et al. Allergic reactions to E. coli L-asparaginase do not affect outcome in childhood B-precursor acute lymphoblastic leukemia: A Children's Oncology Group Study. J Pediatr Hematol Oncol 2007;29(9):627-32
43. Vrooman LM, Neuberg DS, Stevenson KE, et al. Dexamethasone and individualized asparaginase dosing are each associated with superior event-free survival in childhood acute lymphoblastic leukemia: Results from DFCI-ALL consortium protocol 00-01. ASH Annu Meeting Abstr 2009;114(22):321
44. Silverman LB, Stevenson KE, O'Brien JE, et al. Long-term results of dana-farber cancer institute All consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1985-2000). Leukemia 2010;24(2):320-34
45. Larson RA, Fretzin MH, Dodge RK, Schiffer CA. Hypersensitivity reactions to L-asparaginase do not impact on the remission duration of adults with acute lymphoblastic leukemia. Leukemia 1998;12(5):660-5
46. King OY, Wilbur JR, Mumford DM, Sutow WW. Therapy with Erwinia L-asparaginase in children with acute leukemia after anaphylaxis to E. coli L-asparaginase. Cancer 1974;33(3):611-14
47. Billett AL, Sallan SE, Carls A, Gelber RD. Allergic reactions to Erwinia asparaginase in children with acute lymphoblastic leukemia who had previous allergic reactions to Escherichia coli asparaginase. Cancer 1992;70(1):201-6
48. Ohnuma T, Holland JF, Meyer P. Erwinia carotovora asparaginase in patients with prior anaphylaxis to asparaginase from E. coli Cancer 1972;30(2):376-81
49. Salzer W, Asselin B, Supko J, et al., et al. Administration of Erwinia asparaginase (Erwinase) following allergy to PEG-asparaginase in children and young adults with acute lymphoblastic leukemia treated on AALL07P2 achieves therapeutic nadir serum asparaginase activity: A report from the Children's Oncology Group (COG). ASH Annu Meeting Abstr 2010;116(21):2134
50. Food and Drug Administration. Prescribing Information: ERWINAZE (asparaginase Erwinia chrysanthemi). 2011
51. Pratt CB, Johnson WW. Duration and severity of fatty metamorphosis of the liver following L-asparaginase therapy. Cancer 1971;28(2):361-4
52. Douer D, Yampolsky H, Cohen LJ, et al. Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia. Blood 2007;109(7):2744-50
53. Muller H-J, Beier R, da Palma J, et al. PEG-asparaginase (Oncaspar) 2500 U/m (2) BSA in reinduction and relapse treatment in the ALL/NHL-BFM protocols. Cancer Chemother Pharmacol 2002;49(2):149-54
54. Vieira Pinheiro JP, Wenner K, Escherich G, et al. Serum asparaginase activities and asparagine concentrations in the cerebrospinal fluid after a single infusion of 2,500 IU/m(2) PEG asparaginase in children with ALL treated according to protocol COALL-06-97. Pediatr Blood Cancer 2006;46(1):18-25
55. Silverman LB, Stevenson K, Neuberg D, et al. Intravenous PEG Asparaginase during remission induction for childhood ALL. ASH Annu Meeting Abstr 2006;108(11):1854
56. Moghrabi A, Levy DE, Asselin B, et al. Results of the dana-farber cancer institute all consortium protocol 95-01 for children with acute lymphoblastic leukemia. Blood 2007;109(3):896-904
57. Liu C, Kawedia JD, Cheng C, et al. Clinical utility and implications of asparaginase antibodies in acute lymphoblastic leukemia. Leukemia 2012;2012(9):102
58. Cheung NK, Chau IY, Coccia PF. Antibody response to Escherichia coli Lasparaginase. Prognostic significance and clinical utility of antibody measurement. Am J Pediatr Hematol Oncol 1986;8(2):99-104
59. Woo MH, Hak LJ, Storm MC, et al. Anti-asparaginase antibodies following E. coli asparaginase therapy in pediatric acute lymphoblastic leukemia. Leukemia 1998;12(10):1527-33
60. Avramis V, Avramis E, Hunter W, Long M. Immunogenicity of native or pegylated E. coli and Erwinia asparaginases assessed by ELISA and surface plasmon resonance (SPR-biacore) assays of IgG antibodies (Ab) in sera from patients with acute lymphoblastic leukemia (ALL). Anticancer Res 2009;29(1):299-302
61. Tiwari PN, Zielinski M, Quinn JJ, et al. Assessment of anti-asparaginase (ASNase) antibodies (Ab) and ASNase activity after suspected clinical allergy. ASH Annu Meeting Abstr 2006;108(11):1878
62. Zalewska-Szewczyk B, Gach A, Wyka K, et al. The cross-reactivity of anti-asparaginase antibodies against different L-asparaginase preparations. Clin Exp Med 2009;9(2):113-16
63. Willer A, Gerss J, Konig T, et al. Anti-Escherichia coli asparaginase antibody levels determine the activity of second-line treatment with pegylated E coli asparaginase: A retrospective analysis within the ALL-BFM trials. Blood 2011;118(22):5774-82
64. Killander D, Dohlwitz A, Engstedt L, et al. Hypersensitive reactions and antibody formation during L-asparaginase treatment of children and adults with acute leukemia. Cancer 1976;37(1):220-8
65. Fu C, Sakamoto K. PEG-asparaginase. Expert Opin Pharmacother 2007;8(12):1977-84
66. Oettgen HF, Stephenson PA, Schwartz MK, et al. Toxicity of E. coli L-asparaginase in man. Cancer 1970;25(2):253-78
67. Dinndorf P, Gootenberg J, Cohen M, et al. FDA drug approval summary: Pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL). Oncologist 2007;12(8):991-8
68. Holcenberg J. Optimal asparaginase therapy. J Pediatr Hematol Oncol 2004;26(5):273-4
69. Armstrong JK, Hempel G, Koling S, et al. Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients. Cancer 2007;110(1):103-11
70. Kawedia JD, Liu C, Pei D, et al. Dexamethasone exposure and asparaginase antibodies affect relapse risk in acute lymphoblastic leukemia. Blood 2012;119(7):1658-64
71. Duval M, Suciu S, Ferster A, et al. Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: Results f a randomized European Organisation for Research and Treatment of Cancer-Children's Leukemia Group phase 3 trial. Blood 2002;99(8):2734-9
72. Vrooman LM, Supko JG, Neuberg DS, et al. Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia. Pediatr Blood Cancer 2010;54(2):199-205
73. Eden OB, Shaw MP, Lilleyman JS, Richards S. Non-randomised study comparing toxicity of Escherichia coli and Erwinia asparaginase in children with leukaemia. Med Pediatr Oncol 1990;18(6):497-502
74. Salzer WL, Devidas M, Shuster JJ, et al. Intensified PEG-L-asparaginase and antimetabolite-based therapy for treatment of higher risk precursor-B acute lymphoblastic leukemia: A report from the Children's Oncology Group. J Pediatr Hematol Oncol 2007;29(6):369-75
75. Harris MB, Shuster JJ, Pullen J, et al. Treatment of children with early pre-B and pre-B acute lymphocytic leukemia with antimetabolite-based intensification regimens: A Pediatric Oncology Group Study. Leukemia 2000;14(9):1570-6
76. Schrey D, Borghorst S, Lanvers-Kaminsky C, et al. Therapeutic drug monitoring of asparaginase in the ALL-BFM 2000 protocol between 2000 and 2007. Pediatr Blood Cancer 2010;54(7):952-8
77. Albertsen BK, Schroder H, Jakobsen P, et al. Monitoring of Erwinia asparaginase therapy in childhood ALL in the Nordic countries. Br J Clin Pharmacol 2001;52(4):433-7
78. Alize Pharma. Alize Pharma licenses its ASPAREC- therapy for Treatment of Acute Lymphoblastic Leukemia (ALL) to EUSA Pharma. Available from: Http://www.alz-pharma.com/anglais/pdf/Alize-Pharma-120202-EUSA- ASPAREC%28R%29-EN.pdf 2012
79. Allas S, Sahakian P, Fichtner I, Abribat T. Pharmacokinetics and pharmacodynamics in mice of a pegylated recombinant erwinia chrysanthemi-derived L-asparaginase. ASH Annu Meeting Abstr 2009;114(22):2033
80. Vieira Pinheiro JP, Muller HJ, Schwabe D, et al. Drug monitoring of low-dose PEG-asparaginase (Oncaspar) in children with relapsed acute lymphoblastic leukaemia. Br J Haematol 2001;113(1):115-19